The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VNRX | -54.63% | -90.79% | -37.93% | -90% |
| S&P | +13.14% | +87.24% | +13.37% | +490% |
VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.
No news articles found for VolitionRx.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.63M | 32.2% |
| Gross Profit | $0.32M | 124.6% |
| Gross Margin | 50.74% | 20.9% |
| Market Cap | $73.04M | 31.9% |
| Market Cap / Employee | $0.86M | 0.0% |
| Employees | 85 | -22.7% |
| Net Income | -$5.41M | 7.8% |
| EBITDA | -$4.79M | 13.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.20M | -96.3% |
| Accounts Receivable | $0.31M | -1.1% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $8.51M | 82.9% |
| Short Term Debt | $2.75M | 123.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -239.21% | -44.7% |
| Return On Invested Capital | -393.61% | 45.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.47M | 38.5% |
| Operating Free Cash Flow | -$3.47M | 36.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -2.58 | -2.20 | -2.76 | -2.22 | -2.92% |
| Price to Sales | 46.74 | 42.06 | 59.14 | 49.90 | 21.48% |
| Price to Tangible Book Value | -2.54 | -2.17 | -2.73 | -2.20 | -2.39% |
| Enterprise Value to EBITDA | -10.81 | -11.23 | -14.29 | -17.36 | 84.29% |
| Total Debt | $5.82M | $7.37M | $10.94M | $11.26M | 91.27% |
No podcast episodes available.
VNRX earnings call for the period ending September 30, 2021.
VNRX earnings call for the period ending June 30, 2021.
VNRX earnings call for the period ending March 31, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
